Regeneron Pharmaceuticals Inc vs Sea Limited — how do they compare? Regeneron Pharmaceuticals Inc trades at $652.76 (market cap $70.79B), while Sea Limited trades at $105.12 (market cap $65.08B). The key difference: Regeneron Pharmaceuticals Inc and Sea Limited are close in size by market cap, and Regeneron Pharmaceuticals Inc pays a 0.56% dividend while Sea Limited pays none. Which is the better fit depends on your goals.
| REGN | SE | |
|---|---|---|
Market Cap | $70.79B | $65.08B |
Sector | Health | Media |
52-Week High | $812.27 | $196.50 |
52-Week Low | $545.46 | $78.16 |
Enterprise Value | $64.74B | $58.13B |
Dividend Yield | 0.56% | — |
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →Sea Limited offers information technology services. The Company provides online personal computer and mobile digital content, e-commerce, and payment platforms. Sea serves customers worldwide.
Read more on SE →